{"id":7976,"date":"2019-11-09T00:00:00","date_gmt":"2019-11-09T05:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/"},"modified":"2023-06-14T18:14:30","modified_gmt":"2023-06-14T22:14:30","slug":"common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease","status":"publish","type":"news_release","link":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/","title":{"rendered":"Common muscle relaxant linked to severe confusion in patients with kidney disease"},"content":{"rendered":"<p>One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after being prescribed a common muscle relaxant.<\/p>\n<p>A new study from <strong>ICES Western<\/strong>, Western University and Lawson Health Research Institute has shown that patients with kidney dysfunction who were prescribed a high dose of the drug baclofen, were more likely to be admitted to hospital for disorientation and confusion, than those who weren&#x2019;t prescribed the drug. Their results were published today in the high impact journal, <em>JAMA<\/em> and are being presented at the same time at the American Society of Nephrology meeting in Washington, D.C.<\/p>\n<div>\n<div class=\"download-section alignwide infographic-download\" id=\"block_3b2b23b1c01a1e78bbb65917f39a83b7\" data-style=\"deep-blue\">\n\t<div class=\"download-section-content\">\n\t\t\t\t<h2>\n\t\t\tInfographic\t\t<\/h2>\n\t\t\n\t\t\t<\/div>\n\t<div class=\"download-section-buttons\">\n\t\t\t\t\t\t<a class=\"download-section-buttons-primary\" href=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/03\/GargBaclofen-1.jpg\" target=\"_blank\"\n\t\t\tdownload\t\t\taria-label=\"Download Infographic (opens in a new tab)\"\t\t>\n\t\t\tDownload Infographic\t\t\t<svg width=\"19\" height=\"19\" viewBox=\"0 0 19 19\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" role=\"presentation\">\n<path d=\"M2.78003 18.8301C2.14282 18.8301 1.59713 18.603 1.14297 18.1488C0.688813 17.6947 0.46212 17.1494 0.462893 16.5129V13.0372H2.78003V16.5129H16.6829V13.0372H19V16.5129C19 17.1502 18.7729 17.6958 18.3188 18.15C17.8646 18.6042 17.3193 18.8308 16.6829 18.8301H2.78003ZM9.73145 14.1958L3.9386 8.40295L5.5606 6.72303L8.57288 9.73531V0.292969H10.89V9.73531L13.9023 6.72303L15.5243 8.40295L9.73145 14.1958Z\" fill=\"#151D5D\"\/>\n<\/svg>\n\t\t<\/a>\n\t\t\n\t\t\t\t\t\t\t\t\t\t<button type=\"button\" class=\"download-section-buttons-secondary\" data-infographic-popup-open=\"block_3b2b23b1c01a1e78bbb65917f39a83b7-infographic-popup\" aria-haspopup=\"dialog\">\n\t\t\t\tClick to View\t\t\t<\/button>\n\t\t\t\t\t\t<\/div>\n\n\t\t<div class=\"infographic-popup\" id=\"block_3b2b23b1c01a1e78bbb65917f39a83b7-infographic-popup\" role=\"dialog\" aria-modal=\"true\" aria-label=\"Infographic\" hidden>\n\t\t<div class=\"infographic-popup-overlay\" data-infographic-popup-close><\/div>\n\t\t<div class=\"infographic-popup-container\">\n\t\t\t<button type=\"button\" class=\"infographic-popup-close\" data-infographic-popup-close aria-label=\"Close infographic\">&times;<\/button>\n\t\t\t<img decoding=\"async\" class=\"infographic-popup-image\" src=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/03\/GargBaclofen-1.jpg\" alt=\"Infographic\">\n\t\t<\/div>\n\t<\/div>\n\t<\/div>\n<\/div>\n<p>&#x201c;When we looked at people with low kidney function (30 per cent or less) who received a high dose of baclofen from their prescriber, approximately one in 25 were being admitted to hospital with severe confusion, typically over the next few days, &#x201c; said <a href=\"\/ices-scientists\/amit-garg\/\">Dr. Amit Garg<\/a>, professor at Western&#x2019;s Schulich School of Medicine &amp; Dentistry and scientist at ICES and Lawson. &#x201c;If you compare that to a group of people who had low kidney function who didn&#x2019;t get baclofen, that risk is less than one in 500, so it&#x2019;s quite a dramatic difference between the two groups.&#x201d;<\/p>\n<p>Video of the researchers explaining the study findings: <a href=\"https:\/\/www.youtube.com\/watch?v=oAIVn59fhgA&amp;feature=youtu.be\" title=\"opens external link\">https:\/\/www.youtube.com\/watch?v=oAIVn59fhgA&amp;feature=youtu.be<\/a><\/p>\n<p>The research was initiated because of observations that nephrologists were noting in clinic at London Health Sciences Centre.<\/p>\n<p>Dr. Peter Blake, professor at Schulich Medicine &amp; Dentistry, Lawson scientist and coauthor on the study says this drug is commonly prescribed for muscle spasms and muscle pain, and is also prescribed off-label for alcoholism, gastro-esophageal reflex disease, and trigeminal neuralgia. He says it is widely prescribed because it has not previously been associated with serious side-effects.&#xa0;<\/p>\n<p>More than eight million prescriptions for the drug were handed out in the United States in 2016, and despite numerous case reports linking baclofen with cognitive symptoms in patients with kidney disease, this is the first population-based clinical study to look at the association between the two.<\/p>\n<p>&#x201c;It came to my clinical attention dealing with patients with advanced kidney failure, that this drug that is generally thought to be relatively harmless, appeared to be the precipitant of severe confusion,&#x201d; said Dr. Blake. &#x201c;These are patients who had previously been very oriented, and they were suddenly extremely confused and when you took a history, we understood that they had recently started this drug, baclofen.&#x201d;<\/p>\n<p>\nUsing ICES data, the research team looked at a group of approximately 16,000 people in Ontario with kidney disease who started a new dose of baclofen between 2007 and 2018. They divided the patients into two groups, a group that received a high dose, and a group that received a low dose of the drug and compared both to a group of almost 300,000 kidney disease patients who were not prescribed the drug at all.\n<\/p>\n<p>About 20 per cent of older adults live with kidney function of less than 60 per cent. The research team found that 1.11 per cent of such patients (108\/9707) who started a high dose of the drug baclofen were admitted to hospital with cognitive-related symptoms, versus 0.42 per cent (26\/6235) with the low dose. They found that the group most at risk had the lowest kidney function, 3.78 per cent of patients with kidney function less than 30 per cent were hospitalized with these symptoms after starting a high dose of baclofen (26\/687).<\/p>\n<p>&#x201c;We found that in current practice most patients are getting a similar dose of baclofen no matter what the level their kidney function is,&#x201d; said Dr. Garg who is concerned about this discrepancy in dosing because prescribing guidelines already suggest a lower dose for patients with kidney dysfunction that isn&#x2019;t being followed. &#x201c;We also found that the risk for hospitalization for severe confusion was higher amongst patients who received doses that were higher versus doses that were lower.&#x201d;<\/p>\n<p>The authors hope this study will better inform physicians and pharmacists about the use of baclofen for patients with kidney disease. &#x201c;This study shows quite clearly the potential harm of this drug. When a patient with low kidney function presents to the hospital with confusion, when their medication list is reviewed baclofen should be considered as a potential culprit. We&#x2019;re hoping regulatory agencies will now take a look at this and perhaps add a new black box warning for baclofen. With this new information prescribers should reconsider risk-benefit, and should be quite cautious before they prescribe this drug. When they believe the drug is indicated, a low dose should be considered, and patients and their families should be warned about what to look out for in terms of side effects.&#x201d;<\/p>\n<p>The authors also say patients should not stop their prescription medications without talking to their doctor.<\/p>\n<p><span class=\"bold\">Broadcast-quality video of the researchers discussing the study is available upon request.<\/span><\/p>\n<h2>\nMEDIA CONTACT<\/h2>\n<p>Crystal Mackay<br \/>\nMedia Relations Officer<br \/>\nSchulich School of Medicine &amp; Dentistry<br \/>\nWestern University<br \/>\nt. 519.661.2111 ext. 80387<br \/>\nc. 519.933.5944<br \/>\n<a href=\"mailto:crystal.mackay@schulich.uwo.ca\">crystal.mackay@schulich.uwo.ca<\/a><br \/>\n<a href=\"https:\/\/twitter.com\/crystalmackay\">@CrystalMackay<\/a><\/p>\n<p><strong><br \/>\nABOUT WESTERN<\/strong><br \/>\nWestern University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.<\/p>\n<p><strong><br \/>\nABOUT THE SCHULICH SCHOOL OF MEDICINE &amp; DENTISTRY<\/strong><br \/>\nThe Schulich School of Medicine &amp; Dentistry at Western University is one of Canada&#x2019;s preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.<\/p>\n<div><div class=\"about-ices-shortcode\"><p><strong>ICES<\/strong> is an independent, non-profit research institute that uses population-based health information to produce knowledge on a broad range of healthcare issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting healthcare needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. In October 2018, the institute formerly known as the Institute for Clinical Evaluative Sciences formally adopted the initialism ICES as its official name. For the latest ICES news, follow us on Twitter: <a href=\"https:\/\/twitter.com\/ICESOntario\" target=\"_blank\" rel=\"noopener\">@ICESOntario<\/a><\/p>\n<\/div><\/div>\n<p><strong><br \/>\nABOUT LAWSON HEALTH RESEARCH INSTITUTE<\/strong><br \/>\nAs the research institute of London Health Sciences Centre and St. Joseph&apos;s Healthcare London, and working in partnership with Western University, Lawson Health Research Institute is committed to furthering scientific knowledge to advance healthcare around the world.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after being prescribed a common muscle relaxant. A new study from ICES Western, Western University and Lawson Health Research Institute has shown that patients with kidney dysfunction who were prescribed a high [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[49,56,31],"class_list":["post-7976","news_release","type-news_release","status-publish","hentry","topic-kidney-disease","topic-pharmacoepidemiology-and-drug-safety","topic-pharmacy"],"acf":{"infographic":[9526],"journal_article":[5620],"research_report":[],"atlas":[],"research_program":[6743],"site":[6739],"ices_scientist":[1242],"announce_or_event":[],"video":[],"iitn_type":false,"iitn_title":"Muscle relaxant tied to severe confusion in CKD patients","iitn_short_title":"","iitn_source_link_url":"https:\/\/www.medpagetoday.com\/meetingcoverage\/asn\/83237","iitn_source_link_text":"MedPage Today","sitecore_item_id":"211EE938-680C-400E-B2CA-3D73177DEE82","sitecore_item_name":"Common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease","sitecore_field_values":"{\n  \"Content\": \"<p>One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after being prescribed a common muscle relaxant.<\/p>n<p>A new study from <strong>ICES Western<\/strong>, Western University and Lawson Health Research Institute has shown that patients with kidney dysfunction who were prescribed a high dose of the drug baclofen, were more likely to be admitted to hospital for disorientation and confusion, than those who weren&rsquo;t prescribed the drug. Their results were published today in the high impact journal, <em>JAMA<\/em> and are being presented at the same time at the American Society of Nephrology meeting in Washington, D.C.<\/p>n<p><a href=\"~\/media\/1AF9253A750E4566B16B2B6327B9C0D2.ashx\" onclick=\"_gaq.push(['_trackEvent','Download', 'GargBaclofenInfographicNovember2019',this.href]);\"><img height=\"204\" alt=\"Baclofen, a common muscle relaxant, linked to severe confusion in patients with kidney disease\" width=\"350\" src=\"~\/media\/A26BA9435B3E416F8E49B71E25211AA2.ashx\" \/><\/a><br \/>n<span class=\"grey\" style=\"font-size: 12px; font-weight: bold; display: block; color: #5b5656;\">Click image to enlarge<\/span><\/p>n<p>&ldquo;When we looked at people with low kidney function (30 per cent or less) who received a high dose of baclofen from their prescriber, approximately one in 25 were being admitted to hospital with severe confusion, typically over the next few days, &ldquo; said <a href=\"~\/link.aspx?_id=95F0CC45E8864729A10CDC4813D54710&amp;_z=z\">Dr. Amit Garg<\/a>, professor at Western&rsquo;s Schulich School of Medicine &amp; Dentistry and scientist at ICES and Lawson. &ldquo;If you compare that to a group of people who had low kidney function who didn&rsquo;t get baclofen, that risk is less than one in 500, so it&rsquo;s quite a dramatic difference between the two groups.&rdquo;<\/p>n<p>Video of the researchers explaining the study findings: <a href=\"https:\/\/www.youtube.com\/watch?v=oAIVn59fhgA&amp;feature=youtu.be\" title=\"opens external link\">https:\/\/www.youtube.com\/watch?v=oAIVn59fhgA&amp;feature=youtu.be<\/a><\/p>n<p>The research was initiated because of observations that nephrologists were noting in clinic at London Health Sciences Centre.<\/p>n<p>Dr. Peter Blake, professor at Schulich Medicine &amp; Dentistry, Lawson scientist and coauthor on the study says this drug is commonly prescribed for muscle spasms and muscle pain, and is also prescribed off-label for alcoholism, gastro-esophageal reflex disease, and trigeminal neuralgia. He says it is widely prescribed because it has not previously been associated with serious side-effects.&nbsp;<\/p>n<p>More than eight million prescriptions for the drug were handed out in the United States in 2016, and despite numerous case reports linking baclofen with cognitive symptoms in patients with kidney disease, this is the first population-based clinical study to look at the association between the two.<\/p>n<p>&ldquo;It came to my clinical attention dealing with patients with advanced kidney failure, that this drug that is generally thought to be relatively harmless, appeared to be the precipitant of severe confusion,&rdquo; said Dr. Blake. &ldquo;These are patients who had previously been very oriented, and they were suddenly extremely confused and when you took a history, we understood that they had recently started this drug, baclofen.&rdquo;<\/p>n<p>nUsing ICES data, the research team looked at a group of approximately 16,000 people in Ontario with kidney disease who started a new dose of baclofen between 2007 and 2018. They divided the patients into two groups, a group that received a high dose, and a group that received a low dose of the drug and compared both to a group of almost 300,000 kidney disease patients who were not prescribed the drug at all.n<\/p>n<p>About 20 per cent of older adults live with kidney function of less than 60 per cent. The research team found that 1.11 per cent of such patients (108\/9707) who started a high dose of the drug baclofen were admitted to hospital with cognitive-related symptoms, versus 0.42 per cent (26\/6235) with the low dose. They found that the group most at risk had the lowest kidney function, 3.78 per cent of patients with kidney function less than 30 per cent were hospitalized with these symptoms after starting a high dose of baclofen (26\/687).<\/p>n<p>&ldquo;We found that in current practice most patients are getting a similar dose of baclofen no matter what the level their kidney function is,&rdquo; said Dr. Garg who is concerned about this discrepancy in dosing because prescribing guidelines already suggest a lower dose for patients with kidney dysfunction that isn&rsquo;t being followed. &ldquo;We also found that the risk for hospitalization for severe confusion was higher amongst patients who received doses that were higher versus doses that were lower.&rdquo;<\/p>n<p>The authors hope this study will better inform physicians and pharmacists about the use of baclofen for patients with kidney disease. &ldquo;This study shows quite clearly the potential harm of this drug. When a patient with low kidney function presents to the hospital with confusion, when their medication list is reviewed baclofen should be considered as a potential culprit. We&rsquo;re hoping regulatory agencies will now take a look at this and perhaps add a new black box warning for baclofen. With this new information prescribers should reconsider risk-benefit, and should be quite cautious before they prescribe this drug. When they believe the drug is indicated, a low dose should be considered, and patients and their families should be warned about what to look out for in terms of side effects.&rdquo;<\/p>n<p>The authors also say patients should not stop their prescription medications without talking to their doctor.<\/p>n<p><span class=\"bold\">Broadcast-quality video of the researchers discussing the study is available upon request.<\/span><\/p>n<h2>nMEDIA CONTACT<\/h2>n<p>Crystal Mackay<br \/>nMedia Relations Officer<br \/>nSchulich School of Medicine &amp; Dentistry<br \/>nWestern University<br \/>nt. 519.661.2111 ext. 80387<br \/>nc. 519.933.5944<br \/>n<a href=\"mailto:crystal.mackay@schulich.uwo.ca\">crystal.mackay@schulich.uwo.ca<\/a><br \/>n<a href=\"https:\/\/twitter.com\/crystalmackay\">@CrystalMackay<\/a><\/p>n<p><strong>nABOUT WESTERN<\/strong><br \/>nWestern University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community.<\/p>n<p><strong>nABOUT THE SCHULICH SCHOOL OF MEDICINE &amp; DENTISTRY<\/strong><br \/>nThe Schulich School of Medicine &amp; Dentistry at Western University is one of Canada&rsquo;s preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.<\/p>n<p><em><span style=\"color: #002060;\">ICES is an independent, non-profit research institute that uses population-based health information to produce knowledge on a broad range of healthcare issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting healthcare needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. In October 2018, the institute formerly known as the Institute for Clinical Evaluative Sciences formally adopted the initialism ICES as its official name. For the latest ICES news, follow us on Twitter: <a href=\"http:\/\/www.twitter.com\/ICESOntario\">@ICESOntario<\/a><\/span><\/em><\/p>n<p><strong>nABOUT LAWSON HEALTH RESEARCH INSTITUTE<\/strong><br \/>nAs the research institute of London Health Sciences Centre and St. Joseph's Healthcare London, and working in partnership with Western University, Lawson Health Research Institute is committed to furthering scientific knowledge to advance healthcare around the world.<\/p>\",\n  \"Title\": \"Common muscle relaxant linked to severe confusion in patients with kidney disease\",\n  \"Short title\": \"Common muscle relaxant causes severe\",\n  \"Teaser image\": \"<image mediaid=\"{A322F4BD-074D-4BD9-A21A-A9A358DE2CFF}\" alt=\"&quot;&quot;\" height=\"\" width=\"\" hspace=\"\" vspace=\"\" \/>\",\n  \"Summary\": \"Patients with kidney dysfunction prescribed a high dose of baclofen, were more likely to be admitted to hospital for disorientation and confusion, than those who weren\u2019t prescribed the drug. \",\n  \"Location\": \"London\",\n  \"In The News\": \"{B3C0EEFE-C1A6-4BA5-8658-BAFD8F0C3047}\",\n  \"ICES Scientists\": \"{95F0CC45-E886-4729-A10C-DC4813D54710}\",\n  \"ICES Locations\": \"{3B4AF7E8-6835-410B-AEB8-360A79CA0ED8}\",\n  \"Research Programs\": \"{92CC48EB-79AA-49F6-8A80-16D185170261}\",\n  \"Posted Date\": \"20191109T000000\",\n  \"Publication Link\": \"<link text=\"Abstract\" linktype=\"internal\" title=\"opens related abstract\" querystring=\"\" target=\"\" id=\"{F95A2CFF-987F-4E18-86D7-971F3D8F9DEF}\" \/>\",\n  \"Related Link\": \"<link text=\"Infographic\" linktype=\"external\" url=\"~\/Publications\/Infographics?year=2019&amp;page=1#GargBaclofen\" anchor=\"\" title=\"opens related infographic\" target=\"\" \/>\",\n  \"Related Link2\": \"<link text=\"ICES in the News | MedPage Today\" linktype=\"external\" url=\"https:\/\/www.medpagetoday.com\/meetingcoverage\/asn\/83237\" anchor=\"\" title=\"opens external link\" target=\"\" \/>\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Newsroom\/News-Releases\/2019\/Common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Common muscle relaxant linked to severe confusion in patients with kidney disease<\/title>\n<meta name=\"description\" content=\"One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Common muscle relaxant linked to severe confusion in patients with kidney disease\" \/>\n<meta property=\"og:description\" content=\"One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T22:14:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/news-releases\\\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/news-releases\\\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\\\/\",\"name\":\"ICES | Common muscle relaxant linked to severe confusion in patients with kidney disease\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2019-11-09T05:00:00+00:00\",\"dateModified\":\"2023-06-14T22:14:30+00:00\",\"description\":\"One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/news-releases\\\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/news-releases\\\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/news-releases\\\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News Releases\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/news-releases\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Common muscle relaxant linked to severe confusion in patients with kidney disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Common muscle relaxant linked to severe confusion in patients with kidney disease","description":"One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Common muscle relaxant linked to severe confusion in patients with kidney disease","og_description":"One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after","og_url":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T22:14:30+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/","url":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/","name":"ICES | Common muscle relaxant linked to severe confusion in patients with kidney disease","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2019-11-09T05:00:00+00:00","dateModified":"2023-06-14T22:14:30+00:00","description":"One in 25 patients with very low kidney function were admitted to hospital with severe confusion and other cognitive-related symptoms a few days after","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/news-releases\/common-muscle-relaxant-linked-to-severe-confusion-in-patients-with-kidney-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"News Releases","item":"https:\/\/www.ices.on.ca\/fr\/news-releases\/"},{"@type":"ListItem","position":3,"name":"Common muscle relaxant linked to severe confusion in patients with kidney disease"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/news_release\/7976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/news_release"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/news_release"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1242"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6739"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6743"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/5620"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/infographic\/9526"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=7976"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=7976"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=7976"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=7976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}